Reuters logo
BRIEF-European Commission approves Merck’S KEYTRUDA (pembrolizumab)
September 5, 2017 / 11:06 AM / 3 months ago

BRIEF-European Commission approves Merck’S KEYTRUDA (pembrolizumab)

Sept 5 (Reuters) - Merck & Co Inc

* European Commission approves Merck’s KEYTRUDA (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, a type of bladder cancer

* Merck & Co Inc - ‍there was no statistically significant difference between KEYTRUDA and chemotherapy with respect to PFS​

* Merck - ‍KEYTRUDA now approved for adults previously treated with platinum-containing chemotherapy, for adults ineligible for cisplatin-containing chemotherapy ​

* Merck- ‍KEYTRUDA approved for use as monotherapy for treatment of locally advanced/metastatic urothelial carcinoma in adults who received prior platinum-containing chemotherapy​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below